We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

178 hedge funds and large institutions have $2.69B invested in Agios Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 66 increasing their positions, 58 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

4% more funds holding

Funds holding: 171 → 178 (+7)

1.21% more ownership

Funds ownership: 95.18% → 96.38% (+1.2%)

13% less capital invested

Capital invested by funds: $3.07B → $2.69B (-$388M)

33% less call options, than puts

Call options by funds: $10.2M | Put options by funds: $15.1M

80% less funds holding in top 10

Funds holding in top 10: 5 → 1 (-4)

Holders
178
Holders Change
+7
Holders Change %
+4.09%
% of All Funds
4.04%
Holding in Top 10
1
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-80%
% of All Funds
0.02%
New
30
Increased
66
Reduced
58
Closed
22
Calls
$10.2M
Puts
$15.1M
Net Calls
-$4.96M
Net Calls Change
-$9.09M

Top Buyers

1
UBS AM
UBS AM
Illinois
+$19.7M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$14.7M
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$14M
4
PI
Putnam Investments
Massachusetts
+$13.3M
5
First Trust Advisors
First Trust Advisors
Illinois
+$10.7M

Top Sellers

1
Capital International Investors
Capital International Investors
California
-$20.5M
2
CI
Capital International
California
-$13.2M
3
QIM
Quantitative Investment Management
Virginia
-$10.3M
4
Invesco
Invesco
Georgia
-$8.69M
5
CWAM
Columbia Wanger Asset Management
Illinois
-$8.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
26
Casdin Capital
New York
$16.9M +$2.52M +40,000 +16%
PAMU
27
Pictet Asset Management (UK)
United Kingdom
$16.5M +$14.7M +233,925 +428%
DM
28
Deerfield Management
New York
$15M +$3.46M +54,984 +26%
Loomis, Sayles & Company
29
Loomis, Sayles & Company
Massachusetts
$14.5M +$2.65M +42,128 +20%
BNP Paribas Asset Management
30
BNP Paribas Asset Management
France
$14.4M -$247K -3,926 -2%
MWNA
31
Marshall Wace North America
New York
$13.4M -$224K -3,556 -1%
Northern Trust
32
Northern Trust
Illinois
$13.3M +$300K +4,774 +2%
PI
33
Putnam Investments
Massachusetts
$13M +$13.3M +211,727 +1,355%
EAM
34
Eventide Asset Management
Massachusetts
$12.2M – – –
Bank of New York Mellon
35
Bank of New York Mellon
New York
$9.95M -$150K -2,376 -1%
Axa
36
Axa
France
$9.9M +$717K +11,394 +7%
Deutsche Bank
37
Deutsche Bank
Germany
$9.74M +$1.43M +22,721 +15%
Jennison Associates
38
Jennison Associates
New York
$9.51M +$12K +190 +0.1%
PP
39
PDT Partners
New York
$8.65M -$2.19M -34,833 -19%
O
40
OppenheimerFunds
New York
$8.13M +$7.8M +124,035 +680%
Legal & General Group
41
Legal & General Group
United Kingdom
$8.09M +$7.88M +125,168 +771%
ACH
42
ArrowMark Colorado Holdings
Colorado
$7.91M – – –
HRCM
43
Hood River Capital Management
Florida
$7.47M +$581K +9,227 +8%
OM
44
Opaleye Management
Massachusetts
$7.43M – – –
BBA
45
Baker Bros. Advisors
New York
$7.36M – – –
Charles Schwab
46
Charles Schwab
California
$6.97M +$376K +5,980 +5%
CBT
47
Capital Bank & Trust
California
$6.24M -$764K -12,135 -10%
TCIM
48
TIAA CREF Investment Management
New York
$6.2M -$280K -4,444 -4%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$6.11M +$4.04M +64,200 +151%
RPAM
50
Rhenman & Partners Asset Management
Sweden
$5.72M +$5.35M +85,000 +567%
1
2
3 4 5

AGIO Hedge Fund Activity: Q4 2017 in Review

178 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2017, worth a combined $2.69B — down 13% from $3.07B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new AGIO positions and 22 closed out — a net gain of 8 holders — while 66 added to existing stakes and 58 trimmed.

The largest buyer was UBS AM, adding an estimated $19.7M. The largest seller was Capital International Investors, cutting an estimated $20.5M.

  • 178 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2017, up from 171 in Q3 2017.
  • Funds reported $2.69B of Agios Pharmaceuticals stock for Q4 2017, down 13% quarter-over-quarter.
  • 30 funds opened new Agios Pharmaceuticals positions in Q4 2017 and 22 closed out, a net change of +8 holders.
  • The largest Agios Pharmaceuticals buyer in Q4 2017 was UBS AM, an estimated $19.7M added.
  • The largest Agios Pharmaceuticals seller in Q4 2017 was Capital International Investors, an estimated $20.5M sold.

Based on aggregated 13F filings for Q4 2017.